Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallant, Joel, Brunetta, Jason, Crofoot, Gordon, Benson, Paul, Mills, Anthony, Brinson, Cynthia, Oka, Shinichi, Cheng, Andrew, Garner, Will, Fordyce, Marshall, Das, Moupali, McCallister, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172523/
https://www.ncbi.nlm.nih.gov/pubmed/27171740
http://dx.doi.org/10.1097/QAI.0000000000001069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172523/
https://www.ncbi.nlm.nih.gov/pubmed/27171740
http://dx.doi.org/10.1097/QAI.0000000000001069

Ejemplares similares